The Clinical Study Of Luofengning No. 2 Prescription In The Treatment Of AMI Patients With Pump Failure Who Did Not Undergo Emergency PCI

BackgroundIn recent years,our economy and society have developed a lot.People live a happier life.The occurrence of cardiovascular diseases are on the rise.The development of percutaneous coronary intervention(PCI)techniques have greatly improved the prognosis of patients with acute myocardial infarction(AMI).However,for patients with acute heart failure after AMI,it is currently recognized that effective treatment methods are limited,such patients are critically ill,rapid progress,high rehospitalization rate,high mortality,and poor prognosis.And many of these patients refuse emergency PCI,or when they get to the hospital,it’s too late for emergency PCI.Therefore,the research on the treatment of such patients has become a hot topic in the medical community.Traditional Chinese medicine is a huge treasure house and is widely used in the treatment of cardiovascular diseases,especially in the treatment of coronary heart disease and heart failure.Professor Wang created the Luo Feng Ning 2(LFN-2)prescription based on the theory of "Endogenous collateral wind".Previous studies have confirmed that it has a good clinical effect on patients with cardio-renal syndrome.In the clinical,the LFN-2 can be applied to patients with acute heart failure and achieved good results.PurposeThe aim of this study is to study the safety and efficacy of the LFN-2 prescription in hospitalized patients with heart failure after acute myocardial infarction who do not accept emergency PCI treatment,and to guide the application of this prescription in clinical practice.And explore the role of’"Endogenous collateral wind" theory in the treatment of acute heart failure.MethodsSixty patients who didn’t accept emergency PCI treatment with myocardial infarction failure and acute heart failure with heart function KillipⅡ-KillipⅢ were randomly divided into the experimental group and the control group.The patients’ medical records,TCM symptom types,laboratory test results were recorded in detail,and the control group was treated with conventional western medicine.The experimental group took the LFN-2 for 14 days.The comparison of the efficacy of the two groups before and after treatment was used to evaluate the improvement of TCM syndrome scores before and after treatment,improvement of left ventricular ejection fraction by echocardiography,major adverse cardiovascular events,death rate,average hospitalization days of discharged patients,and rehospitalization rate within 30 days after discharge.Statistical analysis was performed using SPSS20.0.Results1 There were no significant differences in age,gender,Killip classification,previous revascularization,previous myocardial infarction,previous heart failure,sum TCM syndrome scores,NT-proBNP and LVEF between the two groups before treatment(P>0.05).2 After treatment,the total scores of TCM syndromes of the two groups were reduced,and the treatment group was better than the control group.The total effective rate of the treatment group was 73.3%,as for the control group,it was 40.0%.The difference was statistically significant(P<0.05).Compared with the control group,the improvement of palpitations and asthma were better than that of the control group(P<0.05).3 Before treatment,there was no significance between two groups in NT-proBNP(P>0.05).After treatment,NT-proBNP in the treatment group decreased(P<0.05),and NT-proBNP in the control group didn’t decrease(P>0.05).4 Before treatment,there was no significance between two groups in LVEF(P>0.05).After treatment,LVEF in the treatment group and the control group didn’t increase(P>0.05).5 The major adverse cardiovascular events between two group was no significance(P>0.05).The death rate between two group was no significance(P>0.05).6.The hospital stay in two groups was no significance(P>0.05).The patients who were successfully discharged from hospital in treatment group had a rehospitalizasion rate for 16.7%,and the patients who were successfully discharged from hospital in control group had a rehospitalizasion rate for 43.3%.The difference was statistically significant(P<0.05).7 During the course of medication and after the end of treatment,no drug-related adverse reactions were found in patients with LFN-2.